loader2
Partner With Us NRI

Natco Pharma Ltd share Price Today

Company details

990.15
1,002.00
609.15
1,108.35
6M Return 31.17%
1Y Return 57.88%
Mkt Cap.(Cr) 17,823.24
Volume 214,880
Div Yield 0.56%
OI
-
OI Chg %
-
Volume 214,880

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Steady performance; focus shifts to crop protection…
About The Stock

     Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market.

    • India formulations mainly comprise oncology products (39 brands). For the US, it follows partnership products for risky launches and acquired Dash Pharma for a front-end presence. It has six FDF, two API manufacturing facilities and two crop health sciences units
    • Maiden entry into crop protection was via launch of pheromone product, Natmate PBW for controlling pink bollworm in cotton
    • Q3FY23 revenue break-up - domestic business: 20.7%, international business: 68% (mainly from the US), APIs: 11.3%
Q3FY23

    In line revenues but margin beat

    • Revenue declined 12% YoY to ₹ 493.3 crore
    • EBITDA improved 4.8% YoY to ₹ 106.7 crore and margins increased 347 bps YoY to 21.6%
    • Adjusted PAT declined 22.5% YoY to ₹ 62.3 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Natco Pharma announced Q1FY24 results:

  • Consolidated total revenue of Rs 1,160.2 crore for Q1FY24, as against Rs 918.9 crore for Q1FY23, a growth of 26.3%.
  • The net profit for Q1FY24, on a consolidated basis, was Rs 420.3 crore as against Rs 320.4 crore in Q1FY23, showing 31.2% growth.
  • The company had made a provision of Rs 51.0 crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about Rs 17.0 crore towards special incentives to employees.
  • The Board of Directors has declared an interim dividend of Rs 7/- (350%) per equity share of Rs 2/- each, for the FY24.

 

 

Result PDF

View Other Company Results

Natco Pharma Ltd shares SWOT Analysis

Strengths (7)

  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (4)

  • MFs decreased their shareholding last quarter
  • Declining Revenue every quarter for the past 2 quarters
  • Declining profits every quarter for the past 2 quarters

Opportunity (2)

  • Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
  • Results Screener: Stocks with upcoming results which are seeing positive shifts in share price

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,005.7
R2 1,012.0
R3 1,017.3
Pivot

1,000.40

S1 994.1
S2 988.8
S3 982.5
EMA SMA
994.0
980.0
941.8
877.3
1,001.4
987.4
936.2
880.9
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Purchase 2024-02-21 1039.15 198742 BSE
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED Block Sell 2024-02-21 1039.15 198742 BSE
SOCIETE GENERALE Block Purchase 2024-01-25 859.2 662733 BSE
Name Category Shares
V C NANNAPANENI PROMOTER 15.66%
VENKATA SATYA SWATHI KANTAMANI PROMOTER 8.92%
DURGA DEVI NANNAPANENI PROMOTER 1.98%
RAJEEV NANNAPANENI PROMOTER 0.63%
TIME CAP PHARMA LABS PRIVATE LIMITED PROMOTER 9.59%
NATSOFT INFORMATION SYSTEMS PVT LTD PROMOTER 8.81%
Vistra ITCL India Limited A/c Neelima Nannapanenni Trust PROMOTER 2.28%

OUR RESEARCH VIEW

Investment recommendation
Steady performance; focus shifts to crop protection…
Call Date
15 Feb 2023
Entry Price 530.00
Target Price 565.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Natco Pharma Ltd Stocks COMPARISON

Financials( in Cr) Natco Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 995.10 1,531.40 1,399.05 1,051.40 3,910.75
% Change 1.24 0.26 -0.54 5.45 0.47
Mcap Cr 17,823.24 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 2,707.10 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 715.30 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 14.01 39.15 26.62 28.83 75.36
1 Year Return 57.88 60.69 51.61 103.07 19.36
ROCE 17.70 16.79 14.76 16.25 19.30
ROE 15.66 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 4,873.80 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 44,248.95 -31,659.16
LAST 3M 105,886.10 -43,482.14
LAST 6M 173,149.22 48,654.40
LAST 12M 264,707.07 127,969.33
Natco Pharma Limited - Loss of Share Certificates

May 17, 2024 l NSE Announcement

Natco Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 15, 2024 l NSE Announcement

Natco Pharma Limited - Other General Purpose

May 14, 2024 l NSE Announcement

Date Action Type Ratio
Feb 26, 2024 Dividend 62.5
Nov 24, 2023 Dividend 62.5
Aug 22, 2023 Dividend 350

Natco Pharma Ltd Information

Stock PE (TTM)
14.01
Promoter Holding
49.71%
Book Value
295.5461
ROCE
17.7%
ROE
15.66%
Description
  • NATCO is an Indian pharmaceutical company that manufactures and markets various pharmaceutical drugs, healthcare products, and chemical formulations. The company also provides chemical manufacturing services on a contract basis. NATCO is headquartered in Hyderabad. In addition to India, NATCO has operations in Canada, Australia, the Philippines, Brazil, and other countries. The company is known as a major producer of cancer-related medicines and drugs for treating Hepatitis-C.

    On 19 December 2022, the market capitalisation of the company was Rs 10,041.56 crore. It reported consolidated sales of Rs 351.1 crore at the end of September 2022. The company is listed on the Bombay Stock Exchange with the code 524816 and the National Stock Exchange with the code NATCOPHARM.

    On 30 September 2022, the company’s shareholding pattern indicated a promoter stake of 48.8%, a 0% stake of foreign institutional investors, and DIIs held a stake of 14.3%, and the public held a stake of 36.9% in the company. The company’s shareholding pattern has remained largely consistent over the past year, with the exception that the FII stake in the company has gone down from around 20% to nil. 

    The company’s board of directors comprises GS Murthy, VC Nannapenni, Rajeev Nannapenni, P S R K Prasad, D G Sharaf, Leela Digumarti, MUR Naidu, and T V Rao, Pavan Bhatt, and others. The auditors are B S R & Associates LLP. On 30 September 2022, the company had a total of 18.26 crore shares outstanding.

    On 19 December 2022, NATCO Ltd.’s share price on BSE was Rs 550.10 and Rs 550 on NSE. The share price touched a 52-week high of Rs 944 and a 52-week low of Rs 545. Its three-month return to investors was -13.56%, while its one-year return was -34.8%.

    As of November 2022, Mirae Asset Emerging Bluechip Direct-Growth had invested Rs 207.7 crore in the company, while ICICI Pru Value Discovery Direct-G and Mirae Asset Midcap Fund Direct-G had invested Rs 163.9 and Rs 116.6 crore, respectively. 

    The company’s peers include Ajanta Pharma, Suven Pharma, and Glenmark Pharma.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Natco House, Road No 2 Banjara Hills, Hyderabad, Telangana, 500033

Tel : 91-040-23547532
Email : investors:natcopharma.co.in
Website : http://www.natcopharma.co.in
Registrar

Venture Capital & Corp. Inv.

AGM Date (Month) : Oct
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 524816
NSE Code : NATCOPHARM
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE987B01026

FAQ’s on Natco Pharma Ltd Shares

You can buy Natco Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Natco Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:58 PM the closing price of Natco Pharma Ltd was Rs.995.10.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:58 PM, the market cap of Natco Pharma Ltd stood at Rs. 17,823.24.

The latest PE ratio of Natco Pharma Ltd as of May 17, 2024 03:58 PM is 14.01

The latest PB ratio of Natco Pharma Ltd as of May 17, 2024 03:58 PM is 0.30

The 52-week high of Natco Pharma Ltd share price is Rs. 1,108.35 while the 52-week low is Rs. 609.15

According to analyst recommendations, Natco Pharma Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app